公开(公告)号：AU2016270373A1

公开(公告)日：2018-01-04

申请号：AU2016270373

申请日：2016-06-03

Applicant: VERTEX PHARMA

Inventor： DAVIES ROBERT J ,  CAO JINGRONG ,  COCKERILL MEGHAN ELISE ,  COLLIER PHILIP NOEL ,  DENINNO MICHAEL PAUL ,  DOYLE ELISABETH ,  FRANTZ JAMES DANIEL ,  GAO HUAI ,  GOLDMAN BRIAN ANTHONY ,  GREY RONALD LEE ,  GRILLOT ANNE-LAURE ,  GU WENXIN ,  HENDERSON JAMES A ,  KRAUSS RAUL EDUARDO ,  KOLPAK ADRIANNE LYNN ,  LIAO YUSHENG ,  MAGAVI SANJAY SHIVAYOGI ,  MALTAIS FRANCOIS ,  MESSERSMITH DAVID ,  PIERCE ALBERT CHARLES ,  PEROLA EMANUELE ,  RYU ELIZABETH JIN-SUN ,  SYKEN JOSHUA ,  WANG JIAN

IPC: C07D249/14 ,  A61K31/4196 ,  A61P25/28 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14

Abstract: The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

公开(公告)号：CA2988306A1

公开(公告)日：2016-12-08

申请号：CA2988306

申请日：2016-06-03

Applicant: VERTEX PHARMA

Inventor： DAVIES ROBERT J ,  CAO JINGRONG ,  COCKERILL MEGHAN ELISE ,  COLLIER PHILIP NOEL ,  DENINNO MICHAEL PAUL ,  DOYLE ELISABETH ,  FRANTZ JAMES DANIEL ,  GAO HUAI ,  GOLDMAN BRIAN ANTHONY ,  GREY RONALD LEE ,  GRILLOT ANNE-LAURE ,  GU WENXIN ,  HENDERSON JAMES A ,  KRAUSS RAUL EDUARDO ,  KOLPAK ADRIANNE LYNN ,  LIAO YUSHENG ,  MAGAVI SANJAY SHIVAYOGI ,  MALTAIS FRANCOIS ,  MESSERSMITH DAVID ,  PIERCE ALBERT CHARLES ,  PEROLA EMANUELE ,  RYU ELIZABETH JIN-SUN ,  SYKEN JOSHUA ,  WANG JIAN

IPC: A61K31/4196 ,  A61P25/28 ,  C07D249/14 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14

Abstract: The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.